At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 404 enrolled
Drug / intervention
GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GSK Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age
In Brief
A Phase 3 clinical trial evaluating GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A) for Herpes Zoster. Completed, enrolled 404 participants across 11 sites.
Detailed Summary
The purpose of this study is to evaluate the impact of reactogenicity of GSK Biologicals' HZ/su vaccine on Quality of Life (QoL) in adults ≥ 50 years of age
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHerpes Zoster
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 2016
Enrollment StartJan 2017
Primary CompletionApr 2017
Study CompletionMay 2018
TodayJul 2026
First PostedDec 1, 2016
Enrollment StartJan 16, 2017
Primary CompletionApr 12, 2017
Study CompletionMay 24, 2018
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 9.6 years ago
Interventions
GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)biological
2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm on a 2 month schedule.